Mabtech Teams With Sai Life Sciences to Establish EYRA Platform Hub in Boston

• Mabtech has entered a strategic collaboration with Sai Life Sciences to expand access to its EYRA multiplex immunology platform in the U.S. 

• The partnership establishes Sai’s Boston site as a hub for delivering immunology assay services to biopharma and biotech customers. 

Mabtech has entered into a strategic collaboration with Sai Life Sciences to expand access to its EYRA multiplex immunology platform in the United States. The agreement establishes Sai’s Boston laboratory as a co-marketed execution and demonstration hub for the platform, supporting immunology research and drug development programs. 

Under the collaboration, the companies will jointly deliver immunology assay services, including multiplex cytokine analysis and phenotyping workflows powered by the EYRA platform. The offering is designed for biopharma and biotech companies working across areas such as immuno-oncology, vaccines, inflammation, and cell therapies. 

Sai Life Sciences, an integrated CRO and contract development and manufacturing organization (CRDMO), will integrate the platform into its discovery and translational research services. The initiative is intended to improve access to immune profiling capabilities and support decision-making earlier in the development process. 

The EYRA platform enables simultaneous detection of multiple analytes in a single run with reduced hands-on time and automation-ready workflows. According to the companies, the system addresses limitations associated with traditional flow-based and plate-based immunoassay methods, enabling more streamlined immune profiling. 

“This installation enables Sai to offer EYRA’s powerful, no-flow multiplex immunology readouts to their broad customer base.”

Kimberlee Parent, Head of U.S. Operations at Mabtech